ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 2,301,581 shares of ArQule stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $2.90, for a total value of $6,674,584.90. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ ARQL opened at $2.85 on Monday. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.03. ArQule, Inc. has a 52 week low of $0.92 and a 52 week high of $3.35. The firm has a market capitalization of $248.26, a P/E ratio of -7.31 and a beta of 0.83.
ArQule (NASDAQ:ARQL) last issued its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.09). During the same period in the prior year, the firm posted ($0.10) earnings per share. equities analysts anticipate that ArQule, Inc. will post -0.31 EPS for the current year.
A number of equities research analysts have recently weighed in on ARQL shares. Leerink Swann raised ArQule from a “market perform” rating to an “outperform” rating in a report on Thursday. Zacks Investment Research upgraded ArQule from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Tuesday, March 20th. Roth Capital initiated coverage on ArQule in a research report on Thursday, February 22nd. They issued a “buy” rating and a $5.00 price target on the stock. B. Riley set a $3.00 price target on ArQule and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, BidaskClub upgraded ArQule from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. ArQule currently has an average rating of “Buy” and an average target price of $4.08.
ArQule Company Profile
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.